Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul 5;373(1750):20170229.
doi: 10.1098/rstb.2017.0229.

Cell-based liver therapies: past, present and future

Affiliations
Review

Cell-based liver therapies: past, present and future

Valeria Iansante et al. Philos Trans R Soc Lond B Biol Sci. .

Abstract

Liver transplantation represents the standard treatment for people with an end-stage liver disease and some liver-based metabolic disorders; however, shortage of liver donor tissues limits its availability. Furthermore, whole liver replacement eliminates the possibility of using native liver as a possible target for future gene therapy in case of liver-based metabolic defects. Cell therapy has emerged as a potential alternative, as cells can provide the hepatic functions and engraft in the liver parenchyma. Various options have been proposed, including human or other species hepatocytes, hepatocyte-like cells derived from stem cells or more futuristic alternatives, such as combination therapies with different cell types, organoids and cell-biomaterial combinations. In this review, we aim to give an overview of the cell therapies developed so far, highlighting preclinical and/or clinical achievements as well as the limitations that need to be overcome to make them fully effective and safe for clinical applications.This article is part of the theme issue 'Designer human tissue: coming to a lab near you'.

Keywords: cell transplantation; hepatocyte transplantation; liver disease; regenerative medicine; stem cells.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests.

References

    1. Puppi J, et al. 2012. Improving the techniques for human hepatocyte transplantation: report from a consensus meeting in London. Cell Transplant. 21, 1–10. ( 10.3727/096368911X566208) - DOI - PubMed
    1. Groth CG, Arborgh B, Björkén C, Sundberg B, Lundgren G. 1977. Correction of hyperbilirubinemia in the glucuronyltransferase-deficient rat by intraportal hepatocyte transplantation. Transplant. Proc. 9, 313–316. - PubMed
    1. Sutherland DE, Numata M, Matas AJ, Simmons RL, Najarian JS. 1977. Hepatocellular transplantation in acute liver failure. Surgery 82, 124–132. - PubMed
    1. Yoshida Y, Tokusashi Y, Lee GH, Ogawa K. 1996. Intrahepatic transplantation of normal hepatocytes prevents Wilson's disease in Long-Evans cinnamon rats. Gastroenterology 111, 1654–1660. ( 10.1016/S0016-5085(96)70029-X) - DOI - PubMed
    1. De Vree JM, Ottenhoff R, Bosma PJ, Smith AJ, Aten J, Oude Elferink RP. 2000. Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis. Gastroenterology 119, 1720–1730. ( 10.1053/gast.2000.20222) - DOI - PubMed

Publication types

MeSH terms